Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Stoppages Often Feasible, but Patient Anxiety Can Be a Hurdle

Thomas R. Collins  |  Issue: September 2020  |  September 11, 2020

Chinnapong / shutterstock.com

Chinnapong / shutterstock.com

Editor’s note: EULAR 2020, the annual European Congress of Rheumatology, which was originally scheduled to be held in Frankfurt, Germany, starting June 3, was moved to a virtual format due to the COVID-19 pandemic.

EULAR 2020 e-CONGRESS—Although reducing medications is a reasonable option for some patients with rheumatoid arthritis (RA)—reducing cost and giving them a sense of normalcy for at least some period of time—such a strategy is not always welcomed with open arms, an expert said at the European e-Congress of Rheumatology. Still, physicians should encourage patients to consider it, said Cornelia Allaart, MD, PhD, associate professor of rheumatology at Leiden University, The Netherlands.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“For so many years we’ve been looking at increasing drugs, getting more drugs, starting [drug therapy] earlier and improving outcomes by getting more and more, and now we’re talking about less and less,” Dr. Allaart said. “It’s a little bit of a new vista, but a very logical step.”

In two trials on drug tapering in which she’s been involved—the BeST trial, and another with a more aggressive initial treatment approach followed by tapering, called IMPROVED—the data suggest slowing or stopping medication administration is possible for many patients. But, Dr. Allaart said, a common hurdle is a patient’s anxiety.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Most patients who are [concerned] about discontinuing their medication are dubious because they fear the flares,” Dr. Allaart said. They also worry that if they stop and then have to restart drug therapy, they’ll have lost ground they’ll never regain in the management of their condition.

Before tapering or stopping medications, rheumatologists need to have “a good conversation” with patients, letting them know that you’re only considering it because they are faring well, with low disease activity.

Why Stop Therapy?

The first, most obvious reason to consider stopping medications is to reduce adverse events. The risk of serious infections has been found to correlate with the prolonged use of glucocorticoids. Other serious side effects of glucocorticoids and other medications, such as biologic disease-modifying anti-rheumatic drugs, may include gastrointestinal bleeds, ulcers, cataracts, edema in the legs, bone fractures and sleep disturbances.1

The data suggest that slowing & stopping medication administration is possible for many patients. But, Dr. Allaart said, a common hurdle is a patient’s anxiety.

Based on the available evidence, however, reducing these events should not be the prime motivation when considering slowing a patient’s medications, Dr. Allaart said.

“These risk factors may entice us to try and taper medications,” she said. “But there’s no proof this will actually lower your risk of infections, … cardiovascular [events]” or other adverse events.

“So why discontinue?” she asked.

A major consideration is that these medications can be very expensive and stopping them, without adverse effects, makes financial sense.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsPatient PerspectiveRheumatoid Arthritis Tagged with:drug stoppageEULARreducing medicationtapering

Related Articles

    Reading Rheum

    July 1, 2007

    Handpicked Reviews of Contemporary Literature

    Target Remission

    March 1, 2007

    Strategies to identify and track remission in your RA patients

    Drug Reduction Strategies, Disease Control for Patients with RA in Remission

    April 20, 2017

    WASHINGTON, D.C.—Clinical aspects of managing patients with rheumatoid arthritis (RA) in remission were discussed by a panel of experts at the 2016 ACR/ARHP Annual Meeting during the session titled Rheumatoid Arthritis—Clinical Aspects IV: Managing Patients in Remission. Among the issues raised were strategies to taper or discontinue biologic therapies, as well as clinical predictors of…

    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    April 15, 2019

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences